- Home
- PHAT vs HUYA Comparison
PHAT vs HUYA Comparison
Compare PHAT & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAT | HUYA |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 989.7M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PHAT | HUYA |
|---|---|---|
| Price | $11.56 | $3.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $19.50 | $3.50 |
| AVG Volume (30 Days) | 898.5K | ★ 1.7M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 66.76% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $83.18 | $8.78 |
| Revenue Next Year | $61.43 | $11.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $2.21 |
| 52 Week High | $18.31 | $4.93 |
Technical Indicators
Market Signals| Indicator | PHAT | HUYA |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 40.95 |
| Support Level | $10.65 | $3.55 |
| Resistance Level | $12.77 | $3.99 |
| Average True Range (ATR) | 0.87 | 0.26 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 14.01 | 0.75 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.